Thalidomide affects the skeletal system of ovariectomized rats

Pharmacological Reports

Volumn 61, Issue 3, 2009, Pages 529-538

  Kaczmarczyk Sedlak, Ilona ^a   Folwarczna, Joanna ^a   Trzeciak, Henryk I ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bone; Osteoporosis; Ovariectomy; Rats; Thalidomide

Indexed keywords

CALCIUM; MINERAL; PHOSPHORUS; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE MINERAL; BONE STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; FEMUR NECK; HISTOLOGY; LIVER WEIGHT; LUMBAR VERTEBRA; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RAT; SPLEEN WEIGHT; THYMUS; TIBIA; UTERUS WEIGHT; WEIGHT GAIN; WISTAR RAT;

ANIMALS; BONE AND BONES; CALCIUM; FEMALE; ORGAN SIZE; OSTEOPOROSIS; OVARIECTOMY; PHOSPHORUS; RATS; RATS, WISTAR; THALIDOMIDE;

EID: 67651146485     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70096-9     Document Type: Article

References (47)

1. Amini-Adle M, Thieulent N, Dalle S, Balme B, Thomas L: Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology, 2007, 214, 58-60.
2. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A et al.: Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 2006, 107, 3098-3105.
3. Ando Y, Fuse E, Figg WD: Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res, 2002, 8, 1964-1973.
4. Arend WP, Dayer JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum, 1995, 38, 151-160.
5. Chabner B, Amrein P, Druker B, Michaelson M, Mitsiades C, Goss P, Ryan D et al.: Antineoplastic agents. In: Goodman and Gilman's the pharmacological basis of therapeutics. Eds. Hardman JG, Limbird LE, Gilman AG, 11th edn. McGraw-Hill Medical Publishing Division, New York, 2006, 1315-1405.
6. Chow JWM: Ovariectomy and Estrogen Replacement in Rodents. In: Bone Research Protocols. Eds. Helfrich MH, Ralston SH, Humana Press, Totowa, 2003, 361-365.
7. Eriksson T, Björkman S, Hoglund P: Clinical pharmacology of thalidomide. Eur J Clin Pharmacol, 2001, 57, 365-376.
8. Folwarczna J, Śliwiński L, Cegieła U, Pytlik M, Kaczmarczyk-Sedlak I, Nowińska B, Janiec W, Trzeciak HI: Raloxifene similarly affects the skeletal system of male and ovariectomized female rats. Pharmacol Rep, 2007, 59, 349-358.
9. Frost HM: Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res, 1969, 3, 211-237.
10. Frost HM, Jee WS: On the rat model of human osteopenias and osteoporoses. Bone Miner, 1992, 18, 227-236.
11. Hamanishi C: Clinical, genetic and epidemiological comparison of the naturally occurring condition with that caused by thalidomide. J Bone Joint Surg Br, 1980, 62, 307-320.
12. Kaczmarczyk-Sedlak I: Modification of bone remodeling by thalidomide in rats (Polish). Habilitation Thesis, Medical University of Silesia, 2008.
13. Kaczmarczyk-Sedlak I, Folwarczna J, Trzeciak HI: Effect of thalidomide on the formation of murine osteoclasts in vitro. Calcif Tissue Int, 2007, 80, Suppl. 1, 91.
14. Kaczmarczyk-Sedlak I, Janiec W, Pytlik M, Śliwiński L, Folwarczna J, Cegieła U, Nowińska B, Barnaś M: Effect of administration of etidronate and retinol on bone mechanical properties in ovariectomized rats. Pharmacol Rep, 2005, 57, 203-211.
15. Kaczmarczyk-Sedlak I, Pytlik M, Śliwiński L, Nowińska B, Juszczyk J: Effect of administration of retinol and etidronate on bone histomorphometric parameters in ovariectomized rats. Acta Pol Pharm Drug Res, 2004, 61, 383-391.
16. Kalu DN: The ovariectomized rat model of postmenopausal bone loss. Bone Miner, 1991, 15, 175-191.
17. Kastritis E, Dimopoulos MA: Thalidomide in the treatment of multiple myeloma. Best Pract Res Clin Haematol, 2007, 20, 681-699.
18. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R: Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology, 1995, 136, 3054-3061.
19. Kumar S, Witzig TE, Rajkumar SV: Thalidomide as an anti-cancer agent. J Cell Mol Med, 2002, 6, 160-174.
20. Lin JH, Yang X, Bostrom MP: Thalidomide blocking of particle-induced TNF-alpha release in vitro. J Orthop Sci, 2003, 8, 79-83.
21. Manolagas SC, Bellido T, Jilka RL: New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130. Int J Immunopharmacol, 1995, 17, 109-116.
22. 8+ T cells. Clin Exp Immunol, 2002, 130, 75-84.
23. Martindale: The complete drug reference. Ed. Sweetman SC, 34th edn. Pharmaceutical Press, London, Chicago. 2006, 2172-2174.
24. McBride WG: Thalidomide embryopathy. Teratology, 1977, 16, 79-82.
25. Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol, 2007, 39, 1489-1499.
26. Nasca MR, Micali G, Cheigh NH, West LE, West DP: Dermatologic and nondermatologic uses of thalidomide. Ann Pharmacother, 2003, 37, 1307-1320.
27. Ozanic-Bulic S, Fassihi H, Mellerio JE, McGrath JA, Atherton DJ: Thalidomide in the management of epidermolysis bullosa prurignosa. Br J Dermatol, 2005, 152, 1332-1334.
28. Pacifici R: Mechanisms of estrogen action on bone. In: Principles of bone biology. Eds. Bilezikian JP, Raisz LG, Rodan GA, 2nd edn. Academic Press, San Diego, San Francisco, New York, Boston, London, Sydney, Tokyo, 2002, 693-705.
29. Paghdal K, Schwartz R: Thalidomide and its dermatologic uses. Acta Dermatovenerol Croat, 2007, 15, 39-44.
30. Plamondon S, Ng SC, Kamm MA: Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther, 2007, 25, 557-567.
31. Pytlik M, Folwarczna J, Janiec W: Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif Tissue Int, 2004, 75, 225-230.
32. Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E et al.: Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc, 2004, 79, 875-882.
33. Rickard D, Harris SA, Turner R, Khosla S, Spelsberg TC: Estrogens and progestins. In: Principles of bone biology. Eds. Bilezikian JP, Raisz LG, Rodan GA, Academic Press, San Diego, San Francisco, New York, Boston, London, Sydney, Tokyo, 2002, 655-675.
34. Rodrigues GB, Passos GF, Di Giunta G, Figueiredo CP, Rodrigues EB, Grumman A Jr, Medeiros R, Calixto JB: Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. Exp Eye Res, 2007, 84, 553-560.
35. Rowland TL, McHugh SM, Deighton J, Dearman RJ, Ewan PW, Kimber I: Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology, 1998, 40, 11-20.
36. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med, 1991, 173, 699-703.
37. Stokkers PC, Hommes DW: New cytokine therapeutics for inflammatory bowel disease. Cytokine, 2004, 28, 167-173.
38. Terpos E, Dimopoulos MA: Myeloma bone disease: pathophysiology and management. Ann Oncol, 2005, 16, 1223-1231.
39. Terpos E, Dimopoulos MA, Sezer O: The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia, 2007, 21, 1875-1884.
40. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E et al.: The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 2005, 19, 1969-1976.
41. Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G et al.: First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol, 2006, 76, 399-404.
42. Vale ML, Cunha FQ, Brito GA, Benevides VM, Ferreira SH, Poole S, Ribeiro RA: Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation. Eur J Pharmacol, 2006, 536, 309-317.
43. Wronski TJ, Yen CF, Scott KS: Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res, 1991, 6, 387-394.
44. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK: Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol, 2005, 153, 254-273.
45. Xiong GS, Wu SM, Wang ZH, Mo JZ, Xiao SD: Effects of thalidomide in experimental models of post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol, 2007, 22, 371-376.
46. Yamazaki I, Yamaguchi H: Characteristics of an ovariectomized osteopenic rat model. J Bone Miner Res, 1989, 4, 13-22.
47. Ye Q, Chen B, Tong Z, Nakamura S, Sarria R, Costabel U, Guzman J: Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J, 2006, 28, 824-831.